<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335075</url>
  </required_header>
  <id_info>
    <org_study_id>P03644</org_study_id>
    <nct_id>NCT00335075</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)</brief_title>
  <official_title>A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate the efficacy and safety of temozolomide
      compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic
      astrocytoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2005</start_date>
  <completion_date type="Actual">February 23, 2006</completion_date>
  <primary_completion_date type="Actual">February 23, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 months, 3 months, and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring of health-related quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Temodal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with temozolomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semustine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated with semustine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.</description>
    <arm_group_label>Temodal group</arm_group_label>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>SCH 052365</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semustine</intervention_name>
    <description>Semustine orally once every 28 days at a dose of 150 mg/m2/day.</description>
    <arm_group_label>Semustine group</arm_group_label>
    <other_name>Methyl-CCNU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior histologic confirmation of glioblastoma, anaplastic astrocytoma.

          -  Evidence of tumor progression or recurrence.

          -  Age &gt;=18 years.

          -  Karnofsky performance status &gt;=60%.

          -  Absolute neutrophil count &gt;=1,500/mm^3, platelet count &gt;=100,000/mm^3, hemoglobin
             &gt;=8g/dL.

          -  Serum BUN and creatinine &lt;1.5 times upper normal limit of testing laboratory (ULN).

          -  Total bilirubin and direct bilirubin &lt;1.5 times ULN.

          -  SGOT, SGPT &lt;3 times ULN; alkaline phosphatase &lt;2 times ULN.

          -  Life expectancy greater than 3 months.

          -  Informed consent obtained.

          -  If palliative radiation is needed, agree to give it prior to initiating chemotherapy
             with study drug. If palliative radiation is required during treatment with study drug,
             the patient should be permanently discontinued from further treatment with study drug.

          -  Women of childbearing potential must use a medically accepted, effective method of
             contraception.

          -  Women of childbearing potential must have a negative serum pregnancy test 24 hours
             prior to administration of study drug.

        Exclusion Criteria:

          -  Chemotherapy (excluding nitrosourea, mitomycin C or vincristine), biologic therapy or
             immunotherapy within 4 weeks, inclusive, prior to study drug administration.

          -  Nitrosourea or mitomycin C administration within 6 weeks, inclusive, prior to study
             drug administration.

          -  Vincristine within 2 weeks prior to study drug administration.

          -  Completion of radiation therapy, interstitial brachytherapy or radiosurgery within 4
             weeks prior to study drug administration.

          -  Surgery within 3 weeks, inclusive, prior to study drug administration.

          -  Acute infection requiring intravenous antibiotics.

          -  Frequent vomiting or medical condition that could interfere with oral medication
             intake (eg, partial bowel obstruction).

          -  Previous or concurrent malignancies at other sites with the exception of surgically
             cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the
             skin.

          -  Known HIV positive or AIDS-related illness.

          -  Pregnant or nursing women.

          -  Men who are not advised to use an effective method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2006</study_first_submitted>
  <study_first_submitted_qc>June 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Semustine</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

